Clinical data
Trade names Lentaron
AHFS/ International Drug Names
ATC code L02BG02 (WHO)
Synonyms 4-Hydroxyandrost-4-ene-3,17-dione
CAS Number 566-48-3 YesY
PubChem (CID) 11273
ChemSpider 10799 YesY
KEGG D07260 YesY
Chemical and physical data
Formula C19H26O3
Molar mass 302.408 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Formestane (trade name Lentaron), also known as 4-hydroxyandrost-4-ene-3,17-dione, is a type I, steroidal, selective aromatase inhibitor.[1] It is used in the treatment of estrogen receptor-positive breast cancer in postmenopausal women. The drug is not active orally, and is instead available only as an intramuscular depot injection. Because of this, it is no longer popular as many orally active aromatase inhibitors have been identified and introduced. Formestane is an analogue of androstenedione.

Formestane is often used to suppress the production of estrogens from anabolic steroids or prohormones. It also acts as a prohormone to 4-hydroxytestosterone, an active steroid which displays weak androgenic activity in addition to acting as a weak aromatase inhibitor.


  1. Pérez Carrión R, Alberola Candel V, Calabresi F, et al. (1994). "Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer". Ann. Oncol. 5 Suppl 7: S19–24. PMID 7873457.
This article is issued from Wikipedia - version of the 12/4/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.